Vera I. Smolyakova

Vera I. Smolyakova

Auto-generated profile, based on publicly available information

Vera I. Smolyakova

Goldberg Research Institute of Pharmacology and Regenerative Medicine, Tomsk National Research Medical Center, Russian Academy of Sciences

Research Focus & Metrics

Academic Career Length

31Years (1996-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 June 2016 in Phytomedicine
Verified
Journal Article
Closed access
DADmitriy N. Atochin
Dmitriy N. Atochin
GCGalina A. Chernysheva
Galina A. Chernysheva
VSVera I. Smolyakova
Vera I. Smolyakova
AOAnton N. Osipenko
Anton N. Osipenko
SLSergey V. Logvinov
Sergey V. Logvinov
MPMark Borisovich Plotnikov
Mark Borisovich Plotnikov

7 November 2010 in Bulletin of Experimental Biology and Medicine
Verified
Journal Article
Closed access
PDF file
MPMark Borisovich Plotnikov
Mark Borisovich Plotnikov
VSV. I. Smolyakova
V. I. Smolyakova
III. S. Ivanov
I. S. Ivanov
GCG. A. Chernisheva
G. A. Chernisheva
AKA. V. Kuchin
A. V. Kuchin
EKE. A. Krasnov
E. A. Krasnov

1 March 2008 in Bulletin of Experimental Biology and Medicine
Verified
Journal Article
Closed access
PDF file
MPMark Borisovich Plotnikov
Mark Borisovich Plotnikov
VSV. I. Smolyakova
V. I. Smolyakova
III. S. Ivanov
I. S. Ivanov
AKA. V. Kuchin
A. V. Kuchin
Irina ChukichevaIrina Chukicheva
Irina Chukicheva
EKE. A. Krasnov
E. A. Krasnov

2 January 2024 in Xenobiotica
Verified
Journal Article
Closed access
GFGalina A. Frelikh
Galina A. Frelikh
EYElena A. Yanovskaya
Elena A. Yanovskaya
ALAlexander Lakeev
Alexander Lakeev
GCGalina A. Chernysheva
Galina A. Chernysheva
VSVera I. Smolyakova
Vera I. Smolyakova
Anastasia KovrizhinaAnastasia Kovrizhina
Anastasia Kovrizhina
1.The dose proportionality and bioavailability of the potential anti-inflammatory and neuroprotec-tive JNK inhibitor 11H-indeno[1,2-b]quinoxalin-11-one oxime (IQ-1) were evaluated by comparing pharmacokinetic parameters after single oral (25, 50 and 100mg/kg) and intravenous (1mg/kg) IQ-1 administration in rats.2. IQ-1 and its major metabolite ketone 11H-indeno[1,2-b]quinoxalin-11-one (IQ-18) were isolated from plasma samples by liquid-liquid extraction. IQ-1 (E-isomer) and IQ-18 were simultaneously quantified in plasma by the validated method of liquid chromatography with triple quadrupole mass spectrometry (HPLC-MS/MS).3. The absolute bioavailability of IQ-1 was <1.5%. Cmax values were 24.72 +/- 4.30, 25.66 +/- 7.11 and 37.61 +/- 3.53ng/mL after single oral administration of IQ-1 at doses of 25, 50 and 100mg/kg, respectively. IQ-1 exhibited dose proportionality at 50-100mg/kg dose levels, whereas its pharma-cokinetics was not dose proportional over the range of 25-50mg/kg. IQ-18 demonstrated the invariance of the dose-normalized Cmax.4.In this study we systematically elucidated the absorption characteristics of IQ-1 in rat gastrointes-tinal tract and provided better understanding of IQ-1 pharmacology for the future development of a new formulations and therapeutic optimisation.

1 August 2016 in Bulletin of Experimental Biology and Medicine
Verified
Journal Article
Closed access
PDF file
GCG. A. Chernysheva
G. A. Chernysheva
VSV. I. Smolyakova
V. I. Smolyakova
EYE. A. Yanovskaya
E. A. Yanovskaya
AKA. V. Kutchin
A. V. Kutchin
Irina ChukichevaIrina Chukicheva
Irina Chukicheva
MPMark Borisovich Plotnikov
Mark Borisovich Plotnikov

30 August 2022 in Drug development & registration
Verified
Journal Article
Open access
PDF file
VBVladimir Bykov
Vladimir Bykov
ABA. V. Bykova
A. V. Bykova
VSV. I. Smolyakova
V. I. Smolyakova
GCG. A. Chernysheva
G. A. Chernysheva
OAO. I. Alyev
O. I. Alyev
АВА. И. Венгеровский
А. И. Венгеровский
Антитромботическая активность производного индолинона – стимулятора растворимой гуанилатциклазы